Nectin Therapeutics Enters Global, Exclusive License Agreement With Immunome; Immunome Receives Exclusive Rights To Panel Of Antibodies Targeting An Undisclosed Target

7/25/24 7:41:52 AM ET

Biotechnology: Pharmaceutical Preparations

Health Care

Get the next $IMNM alert in real time by email

Under the terms of the agreement, Nectin granted Immunome an exclusive, worldwide, all-fields license to monoclonal antibodies that are directed to a single undisclosed target. Immunome will be responsible for the research, development, manufacturing and commercialization of products incorporating these antibodies. Nectin will receive an upfront payment and will be eligible for milestones and royalties.

Get the next $IMNM alert in real time by email

Chat with this insight

Save time and jump to the most important pieces.

Recent Analyst Ratings for
$IMNM

Date	Price Target	Rating	Analyst
5/31/2024	$27.00	Overweight	Piper Sandler
4/30/2024	$24.00	Overweight	JP Morgan
4/15/2024	$35.00	Buy	Guggenheim
1/29/2024	$30.00	Outperform	Leerink Partners
12/19/2023	$12.00	Outperform	Wedbush
10/29/2021	$35.00	Overweight	Cantor Fitzgerald

More analyst ratings

$IMNM
Leadership Updates

Live Leadership Updates

Immunome Appoints Roee Shahar as Executive Vice President, Commercial
Immunome, Inc. (NASDAQ:IMNM), a biotechnology company focused on the development of first-in-class and best-in-class targeted oncology therapies, today announced the appointment of Roee Shahar as Executive Vice President, Commercial. Mr. Shahar brings over two decades of experience, including successfully launching and commercializing oncology and hematology products at Seagen, Pfizer (following the acquisition of Seagen in December 2023) and Eli Lilly & Company. "Roee further strengthens an Immunome team whose members have designed, developed and commercialized innovative targeted therapies for cancer patients," stated Clay Siegall, PhD, President and Chief Executive Officer of Immunome.
10/8/24 8:05:00 AM ET
$IMNM
Biotechnology: Pharmaceutical Preparations
Health Care
STALICLA appoints Dr. Purnanand Sarma, PhD, as Chair of the Board of Directors
Press Release Dr. Sarma brings exceptional expertise in all facets of the pharmaceutical and biotechnology business, from scaling platforms to developing therapeutics Geneva, Switzerland – July 9, 2024 – STALICLA SA, a Swiss neuro precision biotech company dedicated to developing precision medicine-based treatments for neurodevelopmental and neuropsychiatric disorders, such as autism spectrum disorder, announced today the appointment of Dr. Purnanand Sarma, PhD, as Chair of its Board of Directors. Dr. Sarma, who will hold the title of Executive Chairman, will actively support the strategic development of STALICLA, working closely with the CEO, Lynn Durham, and the management team. With an
7/9/24 7:00:00 AM ET
$IMNM
Biotechnology: Pharmaceutical Preparations
Health Care
Immunome Appoints Phil Tsai as Chief Technical Officer
Immunome, Inc. (NASDAQ:IMNM), a biotechnology company focused on developing first-in-class and best-in-class targeted cancer therapies, today announced the appointment of Phil Tsai, PhD, as Chief Technical Officer. Dr. Tsai has nearly three decades of experience in product development, process optimization, and manufacturing, particularly in the area of antibody-drug conjugates (ADCs). "Immunome is excited to add Phil to our management team as we advance our pipeline of differentiated targeted cancer therapies," stated Clay Siegall, PhD, President and Chief Executive Officer of Immunome. "With the Phase 3 trial of AL102 for the treatment of desmoid tumors fully enrolled, two IND filings p
6/27/24 8:00:00 AM ET
$IMNM
Biotechnology: Pharmaceutical Preparations
Health Care

$IMNM
Financials

Live finance-specific insights

Immunome Reports Full Year 2023 Financial Results and Provides Update on Recently Acquired Assets
Topline data for Phase 3 RINGSIDE trial of AL102 expected in first quarter of 2025 IM-1021 and IM-3050 IND filings expected in first quarter of 2025 Current cash expected to fund activities into 2026 Immunome, Inc. (NASDAQ:IMNM), a biotechnology company focused on developing first-in-class and best-in-class targeted cancer therapies, today announced financial results for the full year ended December 31, 2023, and provided an overview of recent developments. "2023 was a transformative year for Immunome as we closed the merger with Morphimmune, advanced our pipeline and expanded the company's leadership team," said Clay B. Siegall, Ph.D., President and Chief Executive Officer. "Th
3/28/24 4:02:00 PM ET
$IMNM
Biotechnology: Pharmaceutical Preparations
Health Care
Immunome Reports Third Quarter 2023 Financial Results
- Completed merger with Morphimmune and concurrent $125 million private placement investment with leading institutional investors - - Clay B. Siegall, Ph.D., former co-founder & CEO of Seagen, Inc., appointed as Chairman and CEO - - Bob Lechleider, M.D., appointed as Chief Medical Officer – - Jean-Jacques Bienaimé, former CEO of BioMarin appointed as member of the Board of Directors - - Cash runway expected to extend into Q1 2026* - Immunome, Inc. (NASDAQ:IMNM), a biotechnology company dedicated to developing first-in-class and best-in-class targeted cancer therapies, today reported financial results for the third quarter ended September 30, 2023 and provided a corporate update.
11/9/23 8:00:00 AM ET
$IMNM
Biotechnology: Pharmaceutical Preparations
Health Care
Immunome Reports Fourth Quarter and Full Year 2022 Financial Results
Immunome, Inc. (NASDAQ:IMNM), a biopharmaceutical company that utilizes its human memory B cell platform to discover and develop first-in-class antibody therapeutics to improve patient care, today reported financial results for the fourth quarter ended December 31, 2022 and provided a corporate update. "Looking back on the past year, the transformative strategic collaboration with AbbVie highlighted the disruptive nature of our discovery platform in finding novel antibody-target pairs based on human memory B-cell response," stated Purnanand Sarma, Ph.D., President and CEO of Immunome. "We look forward to continuing to execute on our momentum throughout the upcoming year as we advance our p
3/16/23 8:00:00 AM ET
$IMNM
Biotechnology: Pharmaceutical Preparations
Health Care

$IMNM
Press Releases

Fastest customizable press release news feed in the world

Immunome Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Immunome, Inc. (the "Company") (NASDAQ:IMNM), a biotechnology company focused on developing first-in-class and best-in-class targeted cancer therapies, announced today that on October 31, 2024, the Compensation Committee of the Company's Board of Directors (the "Compensation Committee") granted inducement awards consisting of non-statutory stock options to purchase 378,800 shares of common stock to 14 new employees under the Company's 2024 Inducement Plan. The Compensation Committee approved the stock options as an inducement material to such employees' employment in accordance with Nasdaq Listing Rule 5635(c)(4). Each stock option has an exercise price equal to $11.47 per share, the Compa
11/1/24 4:05:00 PM ET
$IMNM
Biotechnology: Pharmaceutical Preparations
Health Care
Immunome Presents Compelling Preclinical Data Demonstrating Robust Anti-Tumor Activity for IM-1021
IM-1021 showed superior potency when compared to a competitor in both mantle cell lymphoma and triple-negative breast cancer preclinical models; IND submission expected in 1Q25 HC74, Immunome's proprietary TOP1 ADC payload, shows superior potency, desirable ADME properties, and enhanced efficacy in chemo-resistant cell lines when compared to deruxtecan Immunome, Inc. (NASDAQ:IMNM), a biotechnology company focused on developing first-in-class and best-in-class targeted cancer therapies, recently presented promising preclinical data for IM-1021 and the associated proprietary ADC payload HC74. The results were presented in a poster entitled "Preclinical evaluation of IM-1021, a ROR1-targe
10/29/24 8:00:00 AM ET
$IMNM
Biotechnology: Pharmaceutical Preparations
Health Care
Immunome to Present Poster Highlighting Preclinical Evaluation of IM-1021, a ROR1-Targeted Antibody Drug Conjugate, at the 36th EORTC-NCI-AACR Symposium
Immunome, Inc. (NASDAQ:IMNM), a biotechnology company focused on developing first-in-class and best-in-class targeted cancer therapies, today announced that it will present a poster highlighting preclinical evaluation of IM-1021, a ROR1-targeted antibody drug conjugate (ADC), at the 36th EORTC-NCI-AACR Symposium on Molecular Targets and Cancer Therapeutics in Barcelona on October 24, 2024. Immunome expects to submit an IND for the IM-1021 program to the FDA in the first quarter of 2025. Following the presentation, a copy of the poster will be made available in the "Events & Presentations" portion of Immunome's website. Poster Presentation Details: Title: Preclinical evaluation of IM-102
10/18/24 8:00:00 AM ET
$IMNM
Biotechnology: Pharmaceutical Preparations
Health Care

Nectin Therapeutics Enters Global, Exclusive License Agreement With Immunome; Immunome Receives Exclusive Rights To Panel Of Antibodies Targeting An Undisclosed Target

Chat with this insight

Recent Analyst Ratings for $IMNM

$IMNM Leadership Updates

Live Leadership Updates

Immunome Appoints Roee Shahar as Executive Vice President, Commercial

STALICLA appoints Dr. Purnanand Sarma, PhD, as Chair of the Board of Directors

Immunome Appoints Phil Tsai as Chief Technical Officer

$IMNM Financials

Live finance-specific insights

Immunome Reports Full Year 2023 Financial Results and Provides Update on Recently Acquired Assets

Immunome Reports Third Quarter 2023 Financial Results

Immunome Reports Fourth Quarter and Full Year 2022 Financial Results

$IMNM Insider Purchases

Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

Director Bienaime Jean Jacques bought $97,608 worth of shares (7,000 units at $13.94), increasing direct ownership by 73% to 16,615 units (SEC Form 4)

Bienaime Jean Jacques bought $27,140 worth of shares (2,000 units at $13.57), increasing direct ownership by 26% to 9,615 units (SEC Form 4)

Siegall Clay B bought $1,388,072 worth of shares (100,000 units at $13.88), increasing direct ownership by 31% to 419,636 units (SEC Form 4)

$IMNM Large Ownership Changes

This live feed shows all institutional transactions in real time.

Amendment: SEC Form SC 13D/A filed by Immunome Inc.

SEC Form SC 13G/A filed by Immunome Inc. (Amendment)

SEC Form SC 13G filed by Immunome Inc.

$IMNM Press Releases

Fastest customizable press release news feed in the world

Immunome Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Immunome Presents Compelling Preclinical Data Demonstrating Robust Anti-Tumor Activity for IM-1021

Immunome to Present Poster Highlighting Preclinical Evaluation of IM-1021, a ROR1-Targeted Antibody Drug Conjugate, at the 36th EORTC-NCI-AACR Symposium

$IMNM SEC Filings

Immunome Inc. filed SEC Form 8-K: Entry into a Material Definitive Agreement, Termination of a Material Definitive Agreement, Completion of Acquisition or Disposition of Assets, Unregistered Sales of Equity Securities, Financial Statements and Exhibits

SEC Form S-3ASR filed by Immunome Inc.

Immunome Inc. filed SEC Form 8-K: Other Events, Financial Statements and Exhibits

$IMNM Analyst Ratings

Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

Piper Sandler initiated coverage on Immunome with a new price target

JP Morgan initiated coverage on Immunome with a new price target

Guggenheim initiated coverage on Immunome with a new price target

$IMNM Insider Trading

Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

$IMNM Market Insights

Live Market Insights

Chief Financial Officer Rosett Max exercised 42,000 shares at a strike of $1.05 and sold $230,224 worth of shares (14,380 units at $16.01), increasing direct ownership by 139% to 47,476 units (SEC Form 4)

Director Bienaime Jean Jacques bought $97,608 worth of shares (7,000 units at $13.94), increasing direct ownership by 73% to 16,615 units (SEC Form 4)

Chief Scientific Officer Higgins Jack gifted 2,471 shares, exercised 19,524 shares at a strike of $1.35 and sold $49,072 worth of shares (3,524 units at $13.93) (SEC Form 4)